You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

AGM Statement

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, will hold its Annual General Meeting ("AGM") in London later this morning. At the meeting, the Company's Chairman, Andrew Smith, will make the following statement:

"The year has started well. The Alliance business and the recently acquired Sinclair Healthcare Products business together generated revenues of £30.5 million for the first four months of 2016, which is in line with the Board's expectations.

"Kelo-Cote™, our scar reduction product from the Sinclair portfolio, is now our largest-selling brand. Its sales of £3.0 million in the first four months of 2016 were in line with forecast. Hydromol™, the largest selling brand in the Alliance product range, continued to grow well with sales in the first four months of the year up 7% on the same period in the prior year. The UK consumer healthcare business also continues to develop well, with sales of £2.9 million up 20% on the same period last year, driven by strong growth of Ashton and Parsons™ and Macushield™, which was acquired in February 2015.

"The key activity of combining the two organisations is underway. We are in the process of integrating the Sinclair products under the Alliance name and of aligning the operational capabilities of the enlarged company; both projects are progressing to plan.

“We look forward to the year ahead with confidence.”

Andrew Smith

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.